Skip to content
Head to head

Telix Pharmaceuticals vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: TLX · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

TLX -8.6%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals trades cheapest on trailing earnings.
TLXVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price8.37515.02
Change today-3.90%-1.08%
1-year return-4.6%+22.0%
Market cap$2.84B$130.58B
52-week range6.28 – 13.11412.27 – 568.67
Valuation
P/E (TTM)86.2933.14
P/E percentile, own 5-yr range40th99th
P/B6.836.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-0.0215.32
Net profit (TTM)$-7.11M$3.88B
Revenue (TTM)--$12.95B
Provider revenue period date--2026-09-29
Revenue growth (YoY)--+11.8%
Gross margin53.7%85.5%
Operating margin5.3%33.1%
Net margin3.8%30.7%
Free cash flow (TTM)$7.44M$3.20B
Provider cash-flow period date2023-12-312026-09-29
Ownership & sentiment
Institutional ownership48.2%96.8%
Insider activity (12mo)3 buy / 0 sell28 buy / 22 sell
Short interest (% of float)0.1%1.9%
Analyst consensus100% buy (2)95% buy / 5% hold (21)
Analyst price target$20 (+139%)$624 (+21%)
StockVane view
StockVane Quant RatingD (32)C (68)
Company
Employees1,1846,400
Founded20171989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.